← Back to Search

Pharmacist Alerts for Blood Clot Management

N/A

Recruiting

Led By Geoffrey Barnes, MD

Research Sponsored by University of Michigan

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Timeline

Screening 3 weeks

Treatment Varies

Follow Up month 0, up to 18 months

Awards & highlights

Study Summary

This trial will test whether getting alerts about high-risk prescriptions from pharmacists, instead of doctors, will lead to more changes in prescriptions.

Who is the study for?

This trial is for Michigan Medicine providers with prescribing privileges in ambulatory care settings who prescribe direct oral anticoagulants (DOAC) to patients aged 18 and older. Providers working in inpatient settings or those part of the study team cannot participate.Check my eligibility

What is being tested?

The study tests if alerts about prescriptions sent to pharmacists lead to more prescription changes than alerts sent to prescribers. It also examines if having a pharmacist referral option increases prescription changes when initial-prescribing errors occur.See study design

What are the potential side effects?

Since this trial focuses on communication processes rather than medical treatments, there are no direct side effects from interventions being studied. However, changes in anticoagulant use could indirectly affect patient outcomes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ month 0, up to 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~month 0, up to 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and month 0, up to 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The number (proportion) of notifications (in the existing-prescription notification conditions) that are addressed within 7 days.

Secondary outcome measures

Change in effect size for the existing-prescription notification over time

Change in effect size for the initial alert over time

The number (proportion) of alerts (in the newly prescribed DOAC alert conditions) that are addressed within 7 days.

Trial Design

4Treatment groups

Experimental Treatment

Group I: New-prescription Alert/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions

Group II: New-prescription Alert w/ referral option/ Existing-prescription notification to prescriberExperimental Treatment2 Interventions

Group III: New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacistExperimental Treatment2 Interventions

Group IV: New-prescription Alert / Existing-prescription notification to prescriberExperimental Treatment2 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Agency for Healthcare Research and Quality (AHRQ)FED

399 Previous Clinical Trials

6,817,348 Total Patients Enrolled

3 Trials studying Deep Vein Thrombosis

1,078 Patients Enrolled for Deep Vein Thrombosis

University of MichiganLead Sponsor

1,797 Previous Clinical Trials

6,373,058 Total Patients Enrolled

2 Trials studying Deep Vein Thrombosis

133 Patients Enrolled for Deep Vein Thrombosis

Geoffrey Barnes, MDPrincipal InvestigatorUniversity of Michigan

Media Library

New-prescription Alert Clinical Trial Eligibility Overview. Trial Name: NCT05351749 — N/A

Deep Vein Thrombosis Research Study Groups: New-prescription Alert / Existing-prescription notification to prescriber, New-prescription Alert/ Existing-prescription notification to pharmacist, New-prescription Alert w/ referral option/ Existing-prescription notification to pharmacist, New-prescription Alert w/ referral option/ Existing-prescription notification to prescriber

Deep Vein Thrombosis Clinical Trial 2023: New-prescription Alert Highlights & Side Effects. Trial Name: NCT05351749 — N/A

New-prescription Alert 2023 Treatment Timeline for Medical Study. Trial Name: NCT05351749 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment still available for this clinical trial?

"Yes, according to clinicaltrials.gov this healthcare trial is still enrolling participants. It was initially published on August 1st 2022 and the most recent update was made 3 days later. The research team intends to recruit 5000 people from one centre."

Answered by AI

To what extent has participation been seen in this trial?

"Affirmative. Per the information on clinicaltrials.gov, this medical trial is actively recruiting participants. It was first made available to patients on August 1st 2022 and has been updated as recently as August 3rd of that same year. 5,000 individuals will be admitted across a single site location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use

Geoffrey Barnes 2022. "Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05351749.

All > Afib > Atrial Fibrillation